Drug Target Review

APRIL 7, 2025

The challenge of GPCR drug discovery G protein-coupled receptors (GPCRs) are one of the most desirable and challenging target classes in drug discovery, as their mutation can lead to a wide range of diseases such as cancer, cardiovascular disorders and neurological conditions.

Fragment Screening 52

Fragment Screening Drugs Biophysical Assays Small Molecule 52

Sygnature Discovery

MARCH 14, 2025

Sygnature Discovery offers high throughput screening along with additional hit identification tools including virtual screening, knowledge-based design, and fragment screening. These include quality robust assays, reliable automation, secure data, and the quality of the libraries.

Biochemical Assays 52

Biochemical Assays Fragment Screening Computational Chemistry Assay Development 52

Drug Target Review

NOVEMBER 1, 2023

Could you provide an overview of your research on target directed cancer drug discovery, particularly your focus on protein lagging interactions. I work in the Centre for Cancer Drug Discovery (CCDD) at The Institute of Cancer Research in London, which is an academic drug discovery centre. 2013) 56, 2059-2073.

Fragment Screening 96

Fragment Screening Biochemical Assays Small Molecule Biophysical Assays 96

Sygnature Discovery

JUNE 17, 2024

At Sygnature Discovery, we see biophysics as a core component of drug discovery projects, which can generate data throughout the pipeline. Comprehensive Assay Development for Diverse Applications Our team here at Sygnature Discovery, comprised of expert biophysicists, is highly experienced in a variety of target classes and drug modalities.

Biophysical Assays 52

Biophysical Assays Screening Hits Assay Development Fragment Screening 52